RXi Pharmaceuticals Corporation, an RNA-targeted technologies company, today announced positive results from their second placebo-controlled Phase 1 study with RXI‑109, an sd-rxRNA compound that targets Connective Tissue Growth Factor (CTGF), and is being developed for the treatment of abnormal dermal scars such as hypertrophic scars and keloids in conjunction with scar revision surgery.
In this study, subjects received small skin incisions in their abdomen and were treated with 3 intradermal doses of RXI‑109 over a 2-week period. This dose escalating study consisted of 3 cohorts of 3 healthy volunteers each. Subjects received RXI‑109 on one side of the abdomen, and placebo on the other side.
Subjects were monitored for safety and local and systemic side effects over a total study period of 84 days.
Multiple dermal injections were well tolerated at all doses and treatment with RXI‑109 resulted in dose-dependent silencing of CTGF mRNA in the treated areas.
Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals said that, "We are very pleased with the outcome of this second Phase 1 study. These results show that multiple intradermal injections of RXI‑109 are well tolerated with minimal and mild side effects. He added that, "The work done in the last year has confirmed that our proprietary self-delivering RNAi technology (sd-rxRNA) reduces CTGF mRNA in humans in line with its mechanism of action. Indeed, results from this second study demonstrate that mRNA for CTGF in the incisions is reduced in a dose-dependent manner by RXI‑109 as compared to placebo. Our first Phase 1 study had already shown that a single dose of the drug lowered the actual protein content for CTGF also in a dose-dependent manner. With this exciting outcome, we are ready to embark on Phase 2 development in patients with hypertrophic scars and keloids."
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- Is That A Real Patient Or A Junkie? Now There's An App For That
- How The Higgs Became The Target Of Run 2 At The Tevatron
- You Are Ready To Eat Insects If You Have These Characteristics
- How Neuroscience Is Being Used To Spread Quackery In Business And Education
- Global 'Roadmap' Shows Where To Put Roads Without Costing The Earth
- MOOCs: Learning About Online Learning, One Click At A Time
- Will We Meet ET Microbes On Mars? Why We Should Care Deeply About Them - Like Tigers
- "More precisely: you can say that you have a quantum of an EM wave *after* one combined creation/detection..."
- "What are you planning to do this Month? Here is the list of 200 free online courses that start..."
- "So in this representation every four vector is represented by a 4x4 matrix, but not every 4x4 matrix..."
- "If you look up a text on Quantum Electrodynamics you should find a Psi field for creating and destroying..."
- "You guessed alright, that is a page from the book...Cheers,T...."
- Geochronology and global context of the Charnian Supergroup
- Confirmation of a low pre-extensional geothermal gradient in the Grayback normal
- Scientists get set for simulated nuclear inspection
- Invisible blood in urine may indicate bladder cancer
- Sugar substance 'kills' good HDL cholesterol, new research finds